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Latent Epstein–Barr virus (EBV) infection is strongly associated with B-cell proliferative diseases such as Burkitt’s lymphoma. Here we
show that the oncogenic serine/threonine kinases Pim-1 and Pim-2 enhance the activity of the viral transcriptional activator EBNA2. During
EBV infection of primary B-lymphocytes, the mRNA expression levels of pim genes, especially of pim-2, are upregulated and remain
elevated in latently infected B-cell lines. Thus, EBV-induced upregulation of Pim kinases and Pim-stimulated EBNA2 transcriptional activity
may contribute to the ability of EBV to immortalize B-cells and predispose them to malignant growth.
D 2005 Elsevier Inc. All rights reserved.
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Pim proteins constitute a family of small serine/threonine-
specific cellular protein kinases which efficiently cooperate
with Myc family oncoproteins in murine lymphomagenesis
(Allen et al., 1997; van Lohuizen et al., 1989). Similar
cooperation is likely to occur also in humans, since ex-
pression of pim-1 has been observed to be elevated, e.g., in
leukemias (Amson et al., 1989). In hematopoietic cells, pim-1
or pim-2 genes can be upregulated by interleukins and other
cytokines (Allen et al., 1997; Lilly et al., 1992; Matikainen et
al., 1999), suggesting a role for Pim kinases in cytokine
receptor-initiated signaling. Indeed, Pim-1 has been shown to
protect cytokine-dependent cells from apoptosis (Aho et al.,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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to regulate activities of several hematopoietic cell tran-
scription factors including c-Myb (Leverson et al., 1998),
NFATc1 (Rainio et al., 2002), and STAT5 (Peltola et al.,
2004). Pim-1 stimulates c-Myb activity via its interaction
with the p100 protein (Leverson et al., 1998), which is also
known as the tudor staphylococcal nuclease (Tudor-SN;
Callebaut and Mornon, 1997) recently implicated in RNA
processing (Caudy et al., 2003), but which was first described
as a coactivator for the Epstein–Barr virus (EBV) nuclear
antigen EBNA2 (Tong et al., 1995). EBNA2 is able to
activate transcription of several viral and cellular target genes
through its acidic transactivation domain and is absolutely
essential for the EBV-induced immortalization and trans-
formation of primary B-cells (Cohen and Kieff, 1991). Here
we demonstrate that infection of primary B-lymphocytes by
EBV results in upregulation of pim family gene expression,
and that the Pim kinases in turn enhance transcriptional
activity of EBNA2.05) 201–206
Rapid Communication202Results and discussion
Pim-1 and Pim-2 kinases enhance EBNA2-mediated
transcriptional activation
To examine the potential effects of Pim kinases on
EBNA2 activity, EBV-negative BJAB B-lymphoblasts were
transiently transfected with Gal4-luciferase and g-galactosi-
dase reporter constructs, a plasmid expressing the EBNA2
acidic transactivation domain fused to the Gal4 DNA-
binding domain (pGal4-E2), and different amounts of
plasmids encoding Pim-1 (pSV-pim-1), Pim-2 (pSV-pim-
2), or an N-terminally truncated, kinase-deficient mutant of
Pim-1 (pSV-NT81). Two days after transfection, cells were
collected and their luciferase and g-galactosidase activities
analyzed. As expected (Cohen and Kieff, 1991), expression
of the Gal4-EBNA2 fusion protein alone strongly induced
Gal4-dependent luciferase activity (Fig. 1A). Coexpression
of either Pim-1 (Fig. 1A) or Pim-2 (Fig. 1B) further
enhanced reporter activity up to 10-fold in a dose-dependent
fashion, while the kinase-deficient mutant did not have any
significant effect (Fig. 1A). To control for specificity, we
compared effects of Pim-1 on Gal4-dependent luciferase
activities in transfected BJAB cells coexpressing Gal4 or
Gal4-fusion proteins containing transactivation domainsFig. 1. Both Pim-1 and Pim-2 kinases upregulate activity of the acidic
transactivation domain of EBNA2. BJAB cells were transiently transfected
with 2 Ag of pG5-LUC, 1 Ag of pSV-h-GAL, 0.1 Ag of pGAL4-E2, -VP16
or -PEBP2aB1, and indicated amounts of wild-type (WT) pSV-pim-1, pSV-
pim-2, or the pSV-NT81 mutant of Pim-1. Shown are means and standard
deviations of either actual luciferase activities normalized against h-
galactosidase activities (A and B) or activities relative to those obtained
with Gal4-fusion vectors alone (C).from EBNA2, VP16, and PEBP2aB1. However, activities
of only Gal4-EBNA2 and to a lesser extent Gal4-VP16 were
stimulated by Pim-1 (Fig. 1C). Interestingly, the acidic
transactivation domain of VP16 can also interact with the
p100 coactivator, although less efficiently than that of
EBNA2 (Tong et al., 1995), which may explain the weak
effects of Pim-1 on Gal4-VP16.
The viral LMP1 gene encoding a latent membrane protein
is one of the physiological target genes of EBNA2 that are
turned on during latent EBV infection (Alfieri et al., 1991).
To evaluate potential effects of Pim kinases on the activity of
full-length EBNA2 and on the expression of LMP1, BJAB
cells were cotransfected with a luciferase reporter driven by
the LMP1 promoter (pLMP1-LUC) and plasmids expressing
Pim-1, Pim-2, or EBNA2 (pSG5-EBNA2). As shown in Fig.
2A, Pim-1 and Pim-2 only slightly affected the basal LMP1
reporter activity. By contrast, EBNA2 upregulated the LMP1
reporter by approximately 10-fold, and the stimulatory
effects of EBNA2 were further enhanced by coexpression
of either Pim kinase. Western blot analyses confirmed that
the exogenous Pim proteins were expressed to a similar
extent irrespective of the presence or absence of coexpressed
EBNA2 (Fig. 2B). Taken together, our results from both
Gal4- and LMP1-dependent luciferase assays suggest that
both Pim-1 and Pim-2 potentiate EBNA2-mediated gene
expression in a dose- and kinase activity-dependent manner
by enhancing the activity of the acidic transactivation
domain of EBNA2.
Pim kinases phosphorylate p100, but not EBNA2
Since the kinase activity of Pim-1 was needed for
upregulation of EBNA2 activity (Fig. 1A), the ability of
Pim-1 to phosphorylate the acidic transactivation domain of
EBNA2 was investigated in an in vitro kinase assay.
However, Pim-1 was unable to phosphorylate a bacterially
expressed GST-fusion protein containing the EBNA2 acidic
domain (data not shown). Thus, the phosphorylation-
dependent effects of Pim-1 on EBNA2 activity were more
likely mediated via other components in the EBNA2-
containing protein complex, such as p100, which is a
phosphoprotein in vivo (data not shown) and which can be
phosphorylated in vitro by Pim-1 (Leverson et al., 1998). To
examine whether p100 is a substrate also for Pim-2, we
carried out in vitro kinase assays with bacterially produced
GST-fusion proteins expressing Pim-1, Pim-2, p100, or the
Pim-1-interacting S3 domain of p100 (aa 449–554) identi-
fied in a yeast two-hybrid assay (Leverson et al., 1998).
When the phosphorylated protein products were analyzed by
SDS–PAGE followed by autoradiography, it became evident
that both Pim-1 and Pim-2 can phosphorylate p100 or the S3
fragment to a similar extent (Fig. 3B). Both kinases also
autophosphorylated themselves but did not target the GST
sequences. Silver staining of the gel confirmed that all the
GST-fusion proteins were expressed at comparable levels
(data not shown).
Fig. 3. p100 is phosphorylated by both Pim-1 and Pim-2 kinases in vitro and
is required for full EBNA2 activity. (A) Schematic representation of the
GST- or FLAG-tagged p100 proteins showing the locations of the Pim-1-
interacting domain (S3, dark grey) and the conserved EVES domain (black).
(B) GST-fusion proteins expressing Pim-1 or Pim-2 proteins were incubated
with GST-S3 or GST-p100 in in vitro kinase assays. The phosphorylation
products were analyzed by SDS–PAGE followed by autoradiography. GST
alone () was used as a negative control. (C) BJAB cells were transfected
with 2 Ag of pG5-LUC, 1 Ag of pSV-h-GAL, 0.1 Ag of pGAL4-E2, 3 Ag of
pSV-pim-1, and/or 2.5 Ag of FLAG-tagged p100 derivatives. The luciferase
activities were measured relative to those induced by Gal4-EBNA2 alone.
Fig. 2. Pim kinases enhance EBNA2-mediated transactivation of the LMP1
promoter. (A) BJAB cells were transfectedwith 2 Ag of pLMP1-LUC, 1 Ag of
pSV-h-GAL, and indicated amounts of plasmids encoding Pim-1, Pim-2,
and/or full-length EBNA2. Shown are normalized luciferase activities rela-
tive to those obtainedwith LMP1 reporter alone. (B) Pim-1 and Pim-2 protein
levels were determined by Western blotting from the same cell lysates.
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assays, we coexpressed FLAG-tagged full-length p100 or
two deletion mutants (Fig. 3A) with Gal4-EBNA2 and/or
Pim-1 in BJAB cells and measured Gal4-dependent lucifer-
ase activities. However, ectopically expressed p100 did not
significantly affect Gal4-EBNA2-mediated transactivation
or the ability of Pim-1 to enhance that activity (Fig. 3C),
suggesting that the levels of endogenous p100 protein were
already sufficient in BJAB cells for maximal stimulation
under our assay conditions. Furthermore, when we analyzed
possible negative interfering effects of two p100 deletion
mutants lacking intact Pim-1-interacting domains and one or
more of the N-terminal nuclease folds, we noticed that they
reduced both the basal and the Pim-stimulated Gal4-EBNA2
activity (Fig. 3C). Western blot analysis confirmed that all
the p100 constructs were expressed at comparable levels and
that coexpressed Pim-1 or p100 proteins did not significantly
affect the expression of each other (data not shown). These
results implicate that full-length p100 is needed for the full
activity of the EBNA2 acidic domain, as previously
demonstrated with an EBNA2 mutant which is unable to
interact with p100 and is also transcriptionally inactive (Tong
et al., 1995). While it remains to be elucidated whether p100
is essential also for the enhancing effects of Pim-1 and Pim-
2, it is possible that by recruiting Pim kinases to the EBNA2
transcriptional complex, p100 may enable them to phos-phorylate and regulate some other components of the
complex, such as c-Myb which interacts with p100
independently of EBNA2 (Leverson et al., 1998). Via its
recently reported DNase and RNase activities (Caudy et al.,
2003), p100 might also link Pim kinases to other cellular
processes such as chromatin modifications to facilitate
EBNA2-mediated transactivation.
EBV infection enhances expression of pim genes
Since our data suggested involvement of Pim kinases in
upregulation of EBV-induced gene expression, we wanted to
investigate the physiological relevance of our findings by
Rapid Communication204analyzing the expression patterns of pim genes in EBV-
infected cells. We had previously compared the gene
expression profile of an EBV-negative Burkitt’s lymphoma
cell line (BL41) with that of its EBV-infected counterpart
(BL41/B95) or an EBV-transformed lymphoblastoid cell line
(IB4) (Carter et al., 2002). When data from similar tran-
scriptional profiling experiments were analyzed in further
detail, we found also pim family genes amongst the EBV-
induced genes. In three independent experiments, pim-2
mRNA expression was upregulated by 5- to 12-fold in EBV-
infected BL41 cells and by 2- to 3-fold in IB4 cells as
compared to BL41 cells (data not shown). By contrast, pim-1
transcripts were only slightly more abundant in the EBV-
positive BL41 cells than in the EBV-negative parental cells
and were not significantly elevated in IB4 cells.
To be able to directly evaluate the effects of EBV
infection on pim gene expression in primary B-cells,
purified peripheral blood B-lymphocytes were infected with
the EBV B95-8 strain and RNA samples were collected for
Northern blot analysis at time points indicated in Fig. 4.Fig. 4. Levels of pim-1 and pim-2 mRNAs are upregulated in EBV-infected
primary B-cells and LCLs. CD19-positive B-cells were infected with EBV
and cell samples were collected at indicated days pre (0)- or postinfection.
In addition, five different LCLs were grown for at least 6 weeks after EBV
infection. Total cellular RNA samples were isolated and analyzed by
Northern blotting using pim-1 (A), pim-2 (B), EBNA2 (C), and LMP1 (D)
cDNAs as probes. Equal loading was confirmed by ethidium bromide
(EtBr) staining (E).Again, pim-2 mRNA was more significantly induced than
pim-1 mRNA, following an intriguing kinetics. Its expres-
sion was slightly elevated already within the first day,
together with EBNA2 mRNA. However, after 6 days when
the infected cells had already begun to proliferate and
express also LMP1 mRNA, levels of pim-2 mRNA were
strongly upregulated and remained high at least until the day
15 postinfection. We also measured mRNA expression from
five EBV-immortalized LCLs, which had been cultured for
at least 6 weeks after the initial infection. While these cells
still strongly expressed both EBNA2 and LMP1, the levels
of pim mRNAs had in most cases returned back to those
observed during the first days postinfection. Taken together,
these data indicate that EBV infection substantially, albeit
transiently, upregulates expression of pim genes, especially
of pim-2. Thus, Pim kinases may play an important role
during EBV-induced cellular events.
Interestingly, ectopic expression of LMP1 alone in BL41
cells increases pim-2 mRNA levels (data not shown),
suggesting that LMP1 might be responsible for EBV-induced
upregulation of pim expression, possibly via its ability to
activate NF-nB (Cahir-McFarland et al., 1999) or support
STAT-dependent cytokine signaling (Mosialos, 2001). The
transient nature of pim gene upregulation may in turn be due
to negative feedback via other EBV gene products or via
cellular STAT inhibitors such as SOCS proteins whose
activities are upregulated by Pim kinases (Chen et al., 2002;
Peltola et al., 2004). While further studies are required to
fully characterize the transcriptional regulation of pim genes
in EBV-infected B-cells, their sequential and ultimately
coordinated regulation by EBNA2 and LMP1 may be similar
to that described for CD23 (Alfieri et al., 1991) and are likely
to be more critical for the establishment than maintenance of
the EBV latency.
Pim kinases may promote EBV-induced immortalization and
tumorigenesis
Since Pim kinases can support survival of cytokine-
dependent hematopoietic cells, the transient upregulation of
pim genes during early stages of EBV infection may be
equally important in protecting infected cells from apoptosis
at this critical phase preceding immortalization. Since
LMP1-promoted expression of antiapoptotic proteins is
essential for the survival of LCLs (Cahir-McFarland et al.,
1999), it is possible that Pim kinases are part of a positive
autoregulatory loop that ensures adequate expression of
LMP1, and subsequently protection from apoptosis in newly
infected cells. Thus, inhibition of Pim kinase expression or
activity might affect EBV-induced immortalization of B-
cells or the survival of LCLs.
Type III EBV latency with EBNA2 and LMP1 expression
is observed not only in LCLs, in vitro, but also in EBV-
associated lymphoproliferative diseases (LPD), which can
further transition into Burkitt’s lymphoma (Young et al.,
1989) with deregulated c-myc oncogene expression. Inter-
Rapid Communication 205estingly, micro-array data at the Genomics Institute of the
Novartis Research Foundation Web site (http://expression.
gnf.org) indicates that also pim-2 expression is upregulated
in most BL cell lines. Since both pim-1 and pim-2 genes
strongly cooperate with c-myc in development of murine
pre-B-cell leukemias (Allen et al., 1997; van Lohuizen et al.,
1989), the results presented here suggest that pim and myc
genes may similarly collaborate in EBV-promoted human
malignancies.Materials and methods
Plasmids
The plasmids pSV-pim-1 and pSV-pimNT81 (Aho et al.,
2004), pGal4-EBNA2 and pSG5-EBNA2 (Cohen and Kieff,
1991), pGEX-2T-pim-1 (Rainio et al., 2002), pGEX-2T-pim-
2 (Yan et al., 2003), pGEX-3X-S3 (Leverson et al., 1998),
and the LMP1 promoter-driven luciferase reporter (Han et
al., 2002) have been described previously. pSV-pim-2 was
constructed by PCR from the murine pim-2 cDNA kindly
provided by A. Berns, (Netherlands Cancer Institute,
Amsterdam). pGal4-PEBP2aB1 was kindly provided by Y.
Ito (University of Kyoto, Japan). pGEX-3X-p100 expressing
full-length p100 was subcloned from pET-p100 (Leverson et
al., 1998) and pcDNA3 (Invitrogen)—derived constructs
expressing full-length and truncated p100-FLAG fusion
proteins from pSG5-p100-FLAG (Tong et al., 1995). The
Gal4-luciferase (G5-LUC) and the SV40-driven h-galacto-
sidase (SV-g-GAL) reporters were from Promega and pGal4-
VP16 from Clontech.
Cell culture and reporter assays
The EBV-negative BJAB cells were grown in RPMI 1640
(Sigma) supplemented with 10% fetal calf serum (Gibco)
and antibiotics. These cells were transfected by electro-
poration using reporter and effector plasmids as indicated in
figure legends. Total amounts of transfected DNA samples
were balanced by adding corresponding empty vectors. Two
days after transfection, cells were collected and their
luciferase and g-galactosidase activities analyzed as previ-
ously described (Rainio et al., 2002). The transfection
efficiencies were normalized against h-galactosidase activ-
ities. Shown in figures are means and standard deviations of
representative experiments with duplicate or triplicate
samples.
Western blotting
100 Ag aliquots of protein from luciferase assay samples
were resolved on SDS–PAGE, transferred onto PVDF
membranes (Millipore), and blocked overnight in PBS
containing 0.1% Tween-20 and 5% milk. Proteins of interest
were detected with anti-Pim-1 or anti-Pim-2 antibodies(kindly provided by M. Lilly, Loma Linda University,
CA), followed by HRP-linked secondary anti-mouse anti-
bodies and ECL+Plus reagents (Amersham).
Phosphorylation assays
GST-fusion proteins expressing Pim-1, Pim-2, p100, or
the S3 fragment of p100 (aa 449–554) were grown in
bacteria, purified by glutathione sepharose beads (Amer-
sham Biosciences), and eluted from the beads by 30 mM
glutathione (Sigma). 2.7 Ag aliquots of GST-Pim-1 or -Pim-2
proteins were mixed with 8 Ag of GST, GST-S3, or GST-
p100 proteins in in vitro kinase reactions as previously
described (Rainio et al., 2002) and analyzed by SDS–PAGE
followed by autoradiography. The amounts of proteins
loaded were visualized by silver staining.
B-cell purification and viral infections
Peripheral blood B-cells were prepared from buffy coats
of healthy donors obtained from the Finnish Red Cross
Blood Transfusion Service. Lymphocytes were first purified
using Ficoll-Paque Plus (Amersham Biosciences), after
which the CD19-positive B-cells were selected with CD19
magnetic beads (Miltenyi Biotech) according to manufactur-
er’s instructions. The cells were suspended in Yssel’s
medium (Irvine Scientific) supplemented with 1% human
AB serum (the Finnish Red Cross Blood Transfusion
Service) and incubated overnight prior to EBV infection.
The B95-8 strain of EBV was obtained from 400
concentrated growth medium of the B95-8 marmoset cell
line. For infection, B-cells were pelleted and incubated with
the concentrated virus on ice for 1 h with occasional mixing
and then resuspended at 2  106 cells/ml in serum-
supplemented Yssel’s medium. Samples for mRNA analysis
were collected from EBV-infected B-cells on indicated time
points and fresh Yssel’s medium was added when cells
started to grow and divide.
Northern blot analyses
Total cellular RNA was isolated and analyzed as
previously described (Matikainen et al., 1999) by Northern
blot hybridization with the pim-1, pim-2, EBNA2, and LMP1
probes. The pim-2 probe was cloned from IL-15-treated NK-
92 cells by RT-PCR using oligonucleotides CCCCA-
GAGTGGATCCCTCGACACCAGT and AATGTCCATG-
GATCCCTGTGA-CATGGC. Ethidium bromide (EtBr)
staining of ribosomal RNA bands was used to confirm equal
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